Drug intelligence / Profile preview

XH-001

Development stage: Phase 1
Lead developer: NeoCura
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

XH-001 is an mRNA-based tumor neoantigen vaccine under development for the treatment of advanced solid tumors. It is designed to stimulate the immune system by presenting patient-specific tumor neoantigens, thereby enhancing anti-tumor immunity. The vaccine leverages NeoCura Ag, an artificial intelligence (AI) technology platform developed by NeoCura Bio-Medical Technology to improve precision in diagnosis and treatment of tumors. Clinical trials are ongoing, including studies combining XH-001 with immunocheckpoint inhibitors such as sintilimab for advanced solid tumors and resected pancreatic cancer[1][3][4][5].

Other names: XH001XH-001XH 001

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on XH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XH-001.

Explore the full profile